918879-58-0

Basic information

• Product Name: H2ATSM/A
• CAS NO: 918879-58-0
• Molecular Formula: C₇H₁₅N₇S₂
• Molecular Weight: 261.37
• Mol File: 918879-58-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: H2ATSM/A(CAS DataBase Reference)
• NIST Chemistry Reference: H2ATSM/A(918879-58-0)
• EPA Substance Registry System: H2ATSM/A(918879-58-0)

Safety Data

• Hazardous Substances Data: 918879-58-0(Hazardous Substances Data)

Usage

General Description

H2ATSM/A, also known as diacetyl-bis(N4-methylthiosemicarbazone), is a chemical compound that has shown promise for use in medical imaging and cancer treatment. It is a chelating agent that can bind to certain metal ions, making it useful for imaging techniques such as positron emission tomography (PET). In addition, H2ATSM/A has been studied for its potential to selectively target and kill cancer cells by exploiting the differences in metabolism between normal and cancerous cells. H2ATSM/A has shown potential for improving the accuracy of cancer imaging and for developing targeted cancer therapies. However, further research is needed to fully understand its potential applications and any potential side effects.

Upstream product

• 126971-40-2 diacetyl-2-(4-N-methyl-3-thiosemicarbazone) 
• 2231-57-4 Thiocarbohydrazide 

Downstream Products

• 1239597-25-1 diacetyl-2-(4-N-methyl-3-thiosemicarbazone)-3-(4-N-amino-(4-fluorobenzylamide)-3-thiosemicarbazone) 
• 1208998-89-3 C₁₃H₂₀N₁₀O₃S₂ 
• 1208998-91-7 C₁₀H₁₉N₇OS₂ 
• 1208998-90-6 C₁₃H₂₀N₁₀O₃S₂ 

Relevant articles and documents

Comparison of BTSE-RGD with DOTA-RGD as a potential imaging agent for tumors

RGD and its analogues are very important compounds and can be used as potential tumor-targeting agents. Bisthiosemicarbazone-conjugated RGD (BTSE-RGD) and DOTA-RGD were prepared using a chemical strategy based on peptide synthesis and chemoselective ligations. BTSE-RGD comprises two domains, the first a tumour selective domain and the other a chelating vehicle, for conjugation of radioisotopes. Both compounds were synthesized and labelled with 99mTc and radiochemically analysed by HPLC. The stability of the radioconjugate in the presence of human serum was checked at 37°C up to 8 h. Labelling yield of 96.8 ± 0.32% was obtained, which corresponds to a specific activity in the range of 36-89 MBq μmol-1 for BTSE-RGD. The BTSE-RGD conjugate was examined in vitro for its ability to bind with the αvβ3 receptor. The functionalized BTSE-RGD displayed a binding affinity toward αvβ3 integrin (31.9 ± 6.8 nM) many-fold better than DOTA-RGD. 99mTc-BTSE-RGD showed a slower distribution half-life (T1/2α) and elimination half-life (T1/2β) of 65 ± 0.001 min and 21 h 15 min ± 0.001 min, respectively, in comparison to 99mTc-DOTA-RGD, with T1/2α of 18 ± 0.001 min and T1/2β of 9 h 10 min ± 0.005 min. Biodistribution study showed better tumor-to-muscle ratio for BTSE-RGD, which reaches maximum around 3.5 (% ID) in 2 h, while for DOTA-RGD the maximum was 13.60 at 24 h.